Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Prediabetes is almost always a precursor to type 2 diabetes — but it doesn’t have to lead to that outcome. Experts share healthy steps to reverse the condition.

Everyone is raving about the slimming power of semaglutide medications like Ozempic and Wegovy, which experts say is as ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

This is not a legal document. The explanations and definitions are not legal definitions. In case of a discrepancy between the language in this document and the relevant legislation or regulations, ...

Most Americans are already familiar with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that Novo Nordisk markets as Ozempic and Rybelsus for diabetes, and Wegovy for weight ...

After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 ...

Notes: Safety population, includes all randomized subjects who received at least one dose of study drug or placebo. 80 mg Cohort A = 60 mg daily x 1 wk, 80 mg daily x 3 wks; 80 mg Cohort B = 60 mg ...